658 followers • 13 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Johnson & Johnson
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Vir Biotechnology, Inc.
Inovio Pharmaceuticals, Inc.
FTSE 100 company GlaxoSmithKline is firmly on this Fool's radar!The post If I could buy only 1 FTSE 100 share in this market crash, it'd be this appeared first on The Motley Fool UK.
Zacks Value Trader Highlights: eBay, Pfizer, JPMorgan Chase, Intuitive Surgical and Edwards Lifesciences
With the ongoing erratic movement of most stocks, it's a prudent idea for investors to go for dividend-paying stocks as a regular source of income.
Gilead (GILD) asks the FDA to revoke the Orphan Drug designation granted to its experimental drug, remdesivir, for the treatment of COVID-19.
Stocks are the only thing people won't buy when they go on sale. But with stocks in a bear market, now's your chance to pick up some of the best companies.
Given the urgent need for curing infected COVID-19 patients, let's take a look at the companies developing drugs/treatments for the same.
The Zacks Analyst Blog Highlights: Gilead Sciences, Regeneron, Sanofi, Moderna and Inovio Pharmaceuticals
Due to restrictions on large gatherings, the general meeting of shareholders to approve certain matters for the deal to go through has been postponed to June 30, Mylan said. There were no other changes to previously announced terms or plans pertaining to the deal, previously expected to close in mid-2020, the companies said. The merger, which will bring blockbuster treatments Viagra and Lipitor from Pfizer under one umbrella with Mylan's EpiPen, is part of years-long effort by Pfizer to split into three parts - innovative medicines, lower margin off-patent drugs facing generic competition and consumer healthcare.
Johnson & Johnson Chief Scientific Officer Dr. Paul Stoffels predicts the most vulnerable will begin to receive vaccines within 12 months to prevent COVID-19.
Novavax's (NVAX) NanoFlu, the influenza vaccine candidate for adults aged 65 years and older, meets all the primary and secondary endpoints in late-stage study. Shares rise.